Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;38(4):582-590.
doi: 10.5534/wjmh.190160. Epub 2020 Feb 24.

Obesity and Baseline Estradiol Levels Are Independent Predictors for Initiation of Anastrozole in Hypogonadal Men on Clomiphene Citrate

Sorena Keihani  1 , Nathan J Alder  2 , Philip J Cheng  2 , Gregory J Stoddard  3 , Alexander W Pastuszak  2 , James M Hotaling  2
Affiliations

Obesity and Baseline Estradiol Levels Are Independent Predictors for Initiation of Anastrozole in Hypogonadal Men on Clomiphene Citrate

Sorena Keihani et al. World J Mens Health. 2020 Oct.

Abstract

Purpose: To assess the conversion rate from clomiphene citrate (CC) monotherapy to combination CC+anastrozole (AZ) therapy in hypogonadal men and the predictors associated with the initiation of AZ.

Materials and methods: A retrospective review of records from hypogonadal men treated with CC in a single fertility center was performed from 2013 to 2018. Patient age, body mass index (BMI), blood pressure, and reproductive hormones were obtained at baseline. Obesity was defined as BMI≥30 kg/m². Cox proportional hazards models were used to identify predictors of switching to combination CC+AZ therapy.

Results: A total of 318 men on CC were included. Median (interquartile range) age was 34 years (30-39 years) and patients were followed for a median of 9 months (4-17 months). Of these, 97 (30.5%) were started on CC+AZ therapy. These patients had higher baseline BMI and estradiol, which in multivariable regression were significant predictors for switching to CC+AZ therapy. A threshold of 18.5 pg/mL for baseline estradiol provided the highest accuracy for predicting the addition of AZ after adjusting for baseline BMI and total testosterone levels.

Conclusions: In our practice, following CC monotherapy, 30% of men were initiated on CC+AZ. Obesity (BMI≥30 kg/m²) and baseline estradiol ≥18.5 pg/mL can predict the conversion to combination therapy with addition of AZ. This information can be used to counsel patients and also help to identify patients who can be started on combination therapy upfront.

Keywords: Anastrozole; Clomiphene; Hypogonadism; Infertility, male; Testosterone.

PubMed Disclaimer

Conflict of interest statement

The authors have nothing to disclose.

Figures

Fig. 1
Fig. 1. Kaplan–Meier curves for baseline obesity (A, B) and estradiol ≥18.5 pg/mL (C, D) for prediction of switching to combination clomiphene+anastrozole therapy. (A, C) These graphs are unadjusted curves. (B, D) These graphs are adjusted for baseline age, systolic blood pressure, total testosterone, albumin, and estradiol (for B) or body mass index (BMI) (for D).
See this image and copyright information in PMC

References

    1. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724–731. - PubMed
    1. Patel AS, Leong JY, Ramos L, Ramasamy R. Testosterone is a contraceptive and should not be used in men who desire fertility. World J Mens Health. 2019;37:45–54. - PMC - PubMed
    1. Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423–432. - PubMed
    1. Lo EM, Rodriguez KM, Pastuszak AW, Khera M. Alternatives to testosterone therapy: a review. Sex Med Rev. 2018;6:106–113. - PubMed
    1. Wheeler KM, Sharma D, Kavoussi PK, Smith RP, Costabile R. Clomiphene citrate for the treatment of hypogonadism. Sex Med Rev. 2019;7:272–276. - PubMed